Altered regulation of tau phosphorylation in a mouse model of down syndrome aging

Neurobiology of Aging

Volumn 33, Issue 4, 2012, Pages 828.e31-828.e44

  Sheppard, Olivia ^a   Plattner, Florian ^a   Rubin, Anna ^a,c   Slender, Amy ^b   Linehan, Jacqueline M ^a   Brandner, Sebastian ^a   Tybulewicz, Victor L J ^b   Fisher, Elizabeth M C ^a   Wiseman, Frances K ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer disease; Down syndrome; DYRK1A; GSK 3 ; Phosphorylation; Tau

Indexed keywords

DUAL SPECIFICITY TYROSINE PHOSPHORYLATION REGULATED KINASE; GLYCOGEN SYNTHASE KINASE 3BETA; PHOSPHOTRANSFERASE; TAU PROTEIN; UNCLASSIFIED DRUG;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CONTROLLED STUDY; DOWN SYNDROME; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; FEMALE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REGULATORY MECHANISM; TRISOMY 21;

EID: 84856955428     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2011.06.025     Document Type: Article

References (79)

1. Alessi D.R., Andjelkovic M., Caudwell B., Cron P., Morrice N., Cohen P., Hemmings B.A. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 1996, 15:6541-6551.
2. Alford K.A., Slender A., Vanes L., Li Z., Fisher E.M., Nizetic D., Orkin S.H., Roberts I., Tybulewicz V.L. Perturbed hematopoiesis in the Tc1 mouse model of Down syndrome. Blood 2010, 115:2928-2937.
3. Arendash G.W., Lewis J., Leighty R.E., McGowan E., Cracchiolo J.R., Hutton M., Garcia M.F. Multi-metric behavioral comparison of APPsw and P301L models for Alzheimer's disease: linkage of poorer cognitive performance to tau pathology in forebrain. Brain Res 2004, 1012:29-41.
4. Azorsa D.O., Robeson R.H., Frost D., Meec hoovet B., Brautigam G.R., Dickey C., Beaudry C., Basu G.D., Holz D.R., Hernandez J.A., Bisanz K.M., Gwinn L., Grover A., Rogers J., Reiman E.M., Hutton M., Stephan D.A., Mousses S., Dunckley T. High-content siRNA screening of the kinome identifies kinases involved in Alzheimer's disease-related tau hyperphosphorylation. BMC Genomics 2010, 11:25.
5. Ball S.L., Holland A.J., Hon J., Huppert F.A., Treppner P., Watson P.C. Personality and behaviour changes mark the early stages of Alzheimer's disease in adults with Down's syndrome: findings from a prospective population-based study. Int. J. Geriatr. Psychiatry 2006, 21:661-673.
6. Beasley C., Cotter D., Khan N., Pollard C., Sheppard P., Varndell I., Lovestone S., Anderton B., Everall I. Glycogen synthase kinase-3beta immunoreactivity is reduced in the prefrontal cortex in schizophrenia. Neurosci. Lett 2001, 302:117-120.
7. Bell E.C., Willson M.C., Wilman A.H., Dave S., Silverstone P.H. Differential effects of chronic lithium and valproate on brain activation in healthy volunteers. Hum. Psychopharmacol. Clin. Exp 2005, 20:415-424.
8. Blalock E.M., Geddes J.W., Chen K.C., Porter N.M., Markesbery W.R., Landfield P.W. Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:2173-2178.
9. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991, 82:239-259.
10. Buee L., Bussiere T., Buee-Scherrer V., Delacourte A., Hof P.R. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Brain Res. Rev 2000, 33:95-130.
11. Chin P.C., Majdzadeh N., D'Mello S.R. Inhibition of GSK3beta is a common event in neuroprotection by different survival factors. Brain Res. Mol. Brain Res 2005, 137:193-201.
12. Cohen P., Frame S. The renaissance of GSK3. Nat. Rev. Mol. Cell Biol 2001, 2:769-776.
13. Cowper-Smith C.D., Anger G.J., Magal E., Norman M.H., Robertson G.S. Delayed administration of a potent cyclin dependent kinase and glycogen synthase kinase 3 beta inhibitor produces long-term neuroprotection in a hypoxia-ischemia model of brain injury. Neuroscience 2008, 155:864-875.
14. Cross D.A., Alessi D.R., Cohen P., Andjelkovich M., Hemmings B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995, 378:785-789.
15. Dawson H.N., Cantillana V., Jansen M., Wang H., Vitek M.P., Wilcock D.M., Lynch J.R., Laskowitz D.T. Loss of tau elicits axonal degeneration in a mouse model of Alzheimer's disease. Neuroscience 2010, 169:516-531.
16. Delacourte A., David J.P., Sergeant N., Buée L., Wattez A., Vermersch P., Ghozali F., Fallet-Bianco C., Pasquier F., Lebert F., Petit H., Di Menza C. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology 1999, 52:1158-1165.
17. Dowjat W.K., Adayev T., Kuchna I., Nowicki K., Palminiello S., Hwang Y.W., Wegiel J. Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with Down syndrome. Neurosci. Lett 2007, 413:77-81.
18. Dunlevy L., Bennett M., Slender A., Lana-Elola E., Tybulewicz V.L., Fisher E.M., Mohun T. Down's syndrome-like cardiac developmental defects in embryos of the transchromosomic Tc1 mouse. Cardiovasc. Res 2010, 88:287-295.
19. Endo H., Nito C., Kamada H., Yu F., Chan P.H. Reduction in oxidative stress by superoxide dismutase overexpression attenuates acute brain injury after subarachnoid hemorrhage via activation of Akt/glycogen synthase kinase-3beta survival signaling. J. Cereb. Blood Flow Metab 2007, 27:975-982.
20. Evans D.A., Funkenstein H.H., Albert M.S., Scherr P.A., Cook N.R., Chown M.J., Hebert L.E., Hennekens C.H., Taylor J.O. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA 1989, 262:2551-2556.
21. Flament S., Delacourte A., Mann D.M. Phosphorylation of Tau proteins: a major event during the process of neurofibrillary degeneration. A comparative study between Alzheimer's disease and Down's syndrome. Brain Res 1990, 516:15-19.
22. Galante M., Jani H., Vanes L., Daniel H., Fisher E.M., Tybulewicz V.L., Bliss T.V., Morice E. Impairments in motor coordination without major changes in cerebellar plasticity in the Tc1 mouse model of Down syndrome. Hum. Mol. Genet 2009, 18:1449-1463.
23. Glasson E.J., Sullivan S.G., Hussain R., Petterson B.A., Montgomery P.D., Bittles A.H. The changing survival profile of people with Down's syndrome: implications for genetic counselling. Clin. Genet 2002, 62:390-393.
24. Goedert M., Cohen E.S., Jakes R., Cohen P. p42 MAP kinase phosphorylation sites in microtubule-associated protein tau are dephosphorylated by protein phosphatase 2A1. Implications for Alzheimer's disease [corrected]. FEBS Lett 1992, 312:95-99.
25. Gotz J., Gladbach A., Pennanen L., van Eersel J., Schild A., David D., Ittner L.M. Animal models reveal role for tau phosphorylation in human disease. Biochim. Biophys. Acta Mol. Basis Dis 2010, 1802:860-871.
26. Hernández F., Avila J. The role of glycogen synthase kinase 3 in the early stages of Alzheimers' disease. FEBS Lett 2008, 582:3848-3854.
27. Himpel S., Tegge W., Frank R., Leder S., Joost H.G., Becker W. Specificity determinants of substrate recognition by the protein kinase DYRK1A. J. Biol. Chem 2000, 275:2431-2438.
28. Hooper C., Killick R., Lovestone S. The GSK3 hypothesis of Alzheimer's disease. J. Neurochem 2008, 104:1433-1439.
29. Hu S., Begum A.N., Jones M.R., Oh M.S., Beech W.K., Beech B.H., Yang F., Chen P., Ubeda O.J., Kim P.C., Davies P., Ma Q., Cole G.M., Frautschy S.A. GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals. Neurobiol. Dis 2009, 33:193-206.
30. Hughes K., Nikolakaki E., Plyte S.E., Totty N.F., Woodgett J.R. Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation. EMBO J 1993, 12:803-808.
31. Hur E.M., Zhou F.Q. GSK3 signalling in neural development. Nat. Rev. Neurosci 2010, 11:539-551.
32. Hye A., Kerr F., Archer N., Foy C., Poppe M., Brown R., Hamilton G., Powell J., Anderton B., Lovestone S. Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease. Neurosci. Lett 2005, 373:1-4.
33. Jones E.L., Margallo-Lana M., Prasher V.P., Ballard C.G. The extended tau haplotype and the age of onset of dementia in Down syndrome. Dement. Geriatr. Cogn. Disord 2008, 26:199-202.
34. Jope R.S., Roh M.S. Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. Curr. Drug Targets 2006, 7:1421-1434.
35. Kim L., Kimmel A.R. GSK3, a master switch regulating cell-fate specification and tumorigenesis. Curr. Opin. Genet. Dev 2000, 10:508-514.
36. Kurabayashi N., Hirota T., Sakai M., Sanada K., Fukada Y. DYRK1A and glycogen synthase kinase 3beta, a dual-kinase mechanism directing proteasomal degradation of CRY2 for circadian timekeeping. Mol. Cell. Biol 2010, 30:1757-1768.
37. Lee S.J., Chung Y.H., Joo K.M., Lim H.C., Jeon G.S., Kim D., Lee W.B., Kim Y.S., Cha C.I. Age-related changes in glycogen synthase kinase 3beta (GSK3beta) immunoreactivity in the central nervous system of rats. Neurosci. Lett 2006, 409:134-139.
38. Leroy K., Yilmaz Z., Brion J.P. Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration. Neuropathol. Appl. Neurobiol 2007, 33:43-55.
39. Liang Z., Liu F., Iqbal K., Grundke-Iqbal I., Wegiel J., Gong C.X. Decrease of protein phosphatase 2A and its association with accumulation and hyperphosphorylation of tau in Down syndrome. J. Alzheimers Dis 2008, 13:295-302.
40. Liu F., Grundke-Iqbal I., Iqbal K., Gong C.X. Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur. J. Neurosci 2005, 22:1942-1950.
41. Liu F., Liang Z., Wegiel J., Hwang Y.W., Iqbal K., Grundke-Iqbal I., Ramakrishna N., Gong C.X. Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome. FASEB J 2008, 22:3224-3233.
42. Lockstone H.E., Harris L.W., Swatton J.E., Wayland M.T., Holland A.J., Bahn S. Gene expression profiling in the adult Down syndrome brain. Genomics 2007, 90:647-660.
43. Mandelkow E.M., Drewes G., Biernat J., Gustke N., Van Lint J., Vandenheede J.R., Mandelkow E. Glycogen synthase kinase-3 and the Alzheimer-like state of microtubule-associated protein tau. FEBS Lett 1992, 314:315-321.
44. Mann D.M. Alzheimer's disease and Down's syndrome. Histopathology 1988, 13:125-137.
45. Martí E., Altafaj X., Dierssen M., de la Luna S., Fotaki V., Alvarez M., Pérez-Riba M., Ferrer I., Estivill X. Dyrk1A expression pattern supports specific roles of this kinase in the adult central nervous system. Brain Res 2003, 964:250-263.
46. Matsuo E.S., Shin R.W., Billingsley M.L., Van deVoorde A., O'Connor M., Trojanowski J.Q., Lee V.M. Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau. Neuron 1994, 13:989-1002.
47. Morice E., Andreae L.C., Cooke S.F., Vanes L., Fisher E.M., Tybulewicz V.L., Bliss T.V. Preservation of long-term memory and synaptic plasticity despite short-term impairments in the Tc1 mouse model of Down syndrome. Learn. Mem 2008, 15:492-500.
48. Morishima-Kawashima M., Hasegawa M., Takio K., Suzuki M., Yoshida H., Watanabe A., Titani K., Ihara Y. Hyperphosphorylation of tau in PHF. Neurobiol. Aging 1995, 16:365-371.
49. Muñoz-Montaño J.R., Moreno F.J., Avila J., Diaz-Nido J. Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons. FEBS Lett 1997, 411:183-188.
50. Noble W., Olm V., Takata K., Casey E., Mary O., Meyerson J., Gaynor K., LaFrancois J., Wang L., Kondo T., Davies P., Burns M., Veeranna, Nixon R., Dickson D., Matsuoka Y., Ahlijanian M., Lau L.F., Duff K. Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 2003, 38:555-565.
51. Noshita N., Sugawara T., Lewén A., Hayashi T., Chan P.H. Copper-zinc superoxide dismutase affects Akt activation after transient focal cerebral ischemia in mice. Stroke 2003, 34:1513-1518.
52. O'Doherty A., Ruf S., Mulligan C., Hildreth V., Errington M.L., Cooke S., Sesay A., Modino S., Vanes L., Hernandez D., Linehan J.M., Sharpe P.T., Brandner S., Bliss T.V., Henderson D.J., Nizetic D., Tybulewicz V.L., Fisher E.M. An aneuploid mouse strain carrying human chromosome 21 with down syndrome phenotypes. Science 2005, 309:2033-2037.
53. Papasozomenos S.C., Su Y. Rapid dephosphorylation of tau in heat-shocked fetal rat cerebral explants: prevention and hyperphosphorylation by inhibitors of protein phosphatases PP1 and PP2A. J. Neurochem 1995, 65:396-406.
54. Patrick G.N., Zukerberg L., de la Nikolic M., de la Monte S., Dikkes P., Tsai L.H. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 1999, 402:615-622.
55. Pei J.J., Tanaka T., Tung Y.C., Braak E., Iqbal K., Grundke-Iqbal I. Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J. Neuropathol. Exp. Neurol 1997, 56:70-78.
56. Plattner F., Angelo M., Giese K.P. The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J. Biol. Chem 2006, 281:25457-25465.
57. Pollonini G., Gao V., Rabe A., Palminiello S., Albertini G., Alberini C.M. Abnormal expression of synaptic proteins and neurotrophin-3 in the Down syndrome mouse model Ts65Dn. Neuroscience 2008, 156:99-106.
58. Reynolds L.E., Watson A.R., Baker M., Jones T.A., D'Amico G., Robinson S.D., Joffre C., Garrido-Urbani S., Rodriguez-Manzaneque J.C., Martino-Echarri E., Aurrand-Lions M., Sheer D., Dagna-Bricarelli F., Nizetic D., McCabe C.J., Turnell A.S., Kermorgant S., Imhof B.A., Adams R., Fisher E.M., Tybulewicz V.L., Hart I.R., Hodivala-Dilke K.M. Tumour angiogenesis is reduced in the Tc1 mouse model of Down's syndrome. Nature 2010, 465:813-817.
59. Roberson E.D., Scearce-Levie K., Palop J.J., Yan F., Cheng I.H., Wu T., Gerstein H., Yu G.Q., Mucke L. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007, 316:750-754.
60. Ryoo S.R., Jeong H.K., Radnaabazar C., Yoo J.J., Cho H.J., Lee H.W., Kim I.S., Cheon Y.H., Ahn Y.S., Chung S.H., Song W.J. DYRK1A-mediated hyperphosphorylation of Tau. A functional link between Down syndrome and Alzheimer disease. J. Biol. Chem 2007, 282:34850-34857.
61. Saito M., Chakraborty G., Mao R.F., Paik S.M., Vadasz C., Saito M. Tau phosphorylation and cleavage in ethanol-induced neurodegeneration in the developing mouse brain. Neurochem. Res 2010, 35:651-659.
62. Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307:1098-1101.
63. Shukkur E.A., Shimohata A., Akagi T., Yu W., Yamaguchi M., Murayama M., Chui D., Takeuchi T., Amano K., Subramhanya K.H., Hashikawa T., Sago H., Epstein C.J., Takashima A., Yamakawa K. Mitochondrial dysfunction and tau hyperphosphorylation in Ts1Cje, a mouse model for Down syndrome. Hum. Mol. Genet 2006, 15:2752-2762.
64. Siarey R.J., Kline-Burgess A., Cho M., Balbo A., Best T.K., Harashima C., Klann E., Galdzicki Z. Altered signaling pathways underlying abnormal hippocampal synaptic plasticity in the Ts65Dn mouse model of Down syndrome (vol 98, pg 1266, 2006). J. Neurochem 2006, 99:1320.
65. Siddiqui A., Lacroix T., Stasko M.R., Scott-McKean J.J., Costa A.C., Gardiner K.J. Molecular responses of the Ts65Dn and Ts1Cje mouse models of Down syndrome to MK-801. Genes Brain Behav 2008, 7:810-820.
66. Sutherland C., Leighton I.A., Cohen P. Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling. Biochem. J 1993, 296:15-19.
67. Swatton J.E., Sellers L.A., Faull R.L., Holland A., Iritani S., Bahn S. Increased MAP kinase activity in Alzheimer's and Down syndrome but not in schizophrenia human brain. Eur. J. Neurosci 2004, 19:2711-2719.
68. Swerdlow R.H., Khan S.M. The Alzheimer's disease mitochondrial cascade hypothesis: an update. Exp. Neurol 2009, 218:308-315.
69. Tan W., Cao X., Wang J., Lv H., Wu B., Ma H. Tau hyperphosphorylation is associated with memory impairment after exposure to 1.5% isoflurane without temperature maintenance in rats. Eur. J. Anaesthesiol. 2010, 27:835-841.
70. Truett G.E., Heeger P., Mynatt R.L., Truett A.A., Walker J.A., Warman M.L. Preparation of PCR-quality mouse genomic DNA with hot sodium hydroxide and tris (HotSHOT). BioTechniques 2000, 29:52-54.
71. Tsai L.H., Delalle I., Caviness V.S., Chae T., Harlow E. p35 is a neural-specific regulatory subunit of cyclin-dependent kinase. Nature 1994, 5:371. 419-423.
72. Tseng H.C., Zhou Y., Shen Y., Tsai L.H. A survey of Cdk5 activator p35 and p25 levels in Alzheimer's disease brains. FEBS Lett 2002, 523:58-62.
73. Wadsworth J.D., Powell C., Beck J.A., Joiner S., Linehan J.M., Brandner S., Mead S., Collinge J. Molecular diagnosis of human prion disease. Methods Mol. Biol 2008, 459:197-227.
74. Wegiel J., Dowjat K., Kaczmarski W., Kuchna I., Nowicki K., Frackowiak J., Mazur Kolecka B., Wegiel J., Silverman W.P., Reisberg B., Deleon M., Wisniewski T., Gong C.X., Liu F., Adayev T., Chen-Hwang M.C., Hwang Y.W. The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome. Acta Neuropathol 2008, 116:391-407.
75. Wegiel J., Kuchna I., Nowicki K., Frackowiak J., Dowjat K., Silverman W.P., Reisberg B., Deleon M., Wisniewski T., Adayev T., Chen-Hwang M.C., Hwang Y.W. Cell type- and brain structure-specific patterns of distribution of minibrain kinase in human brain. Brain Res 2004, 1010:69-80.
76. Wiseman F.K., Alford K.A., Tybulewicz V.L., Fisher E.M. Down syndrome-recent progress and future prospects. Hum. Mol. Genet 2009, 18:R75-R83.
77. Woods Y.L., Cohen P., Becker W., Jakes R., Goedert M., Wang X., Proud C.G. The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase. Biochem. J 2001, 355:609-615.
78. Wu D., Pan W. GSK3: a multifaceted kinase in Wnt signaling. Trends Biochem. Sci 2010, 35:161-168.
79. Yu J.T., Chang R.C., Tan L. Calcium dysregulation in Alzheimer's disease: from mechanisms to therapeutic opportunities. Prog. Neurobiol 2009, 89:240-255.